Yuri de Abreu Gomes-Vasconcelos , Pedro Lucas Martins-Santiago , Dalgimar Beserra de Menezes , José Lima de Carvalho Rocha , Rutyleia Alves-Soares , Maria Diana Moreira-Gomes , Francisco Walber Ferreira-da-Silva , Kerly Shamyra da Silva-Alves , José Henrique Leal-Cardoso , Andrelina Noronha Coelho-de-Souza
{"title":"Anti-inflammatory and antioxidative effects of essential oil of Hyptis crenata on the intestinal injuries induced by methotrexate","authors":"Yuri de Abreu Gomes-Vasconcelos , Pedro Lucas Martins-Santiago , Dalgimar Beserra de Menezes , José Lima de Carvalho Rocha , Rutyleia Alves-Soares , Maria Diana Moreira-Gomes , Francisco Walber Ferreira-da-Silva , Kerly Shamyra da Silva-Alves , José Henrique Leal-Cardoso , Andrelina Noronha Coelho-de-Souza","doi":"10.1016/j.prenap.2024.100112","DOIUrl":null,"url":null,"abstract":"<div><div>Methotrexate (MTX) is an important drug for the treatment of cancer and other diseases. However, it induces many gastrointestinal inflammation-related side effects. The essential oil of <em>Hyptis crenata</em> (EOHc) has gastrointestinal protective and anti-inflammatory properties. Therefore, we aimed to investigate the effect of EOHc on MTX-induced intestinal inflammation in rats. Male Wistar rats were administered MTX or Saline for 3 days and EOHc (300 mg/kg) or vehicle for an additional 3 or 7 days. Half of the animal was euthanized 3 days after the end of MTX treatment (inflammation phase) and the remaining half euthanized 4 days later (post-inflammation phase). The MPO levels in the mucositis inflammation-related phase of the MTX-treated group were 284 % of the control in the duodenum (cont: 50,9 ± 9,97 U/mg of protein) and 231 % of the control in the ileum (cont: 30,4 ± 6,60 U/mg of protein). In the EOHc group, the levels were 50 % of control in the duodenum and 113 % in the ileum. During this phase, EOHc prevented the increase in TBARs levels and the decrease in thiol levels in the duodenum and jejunum. In the post-inflammation phase of mucositis, EOHc prevented the gastrointestinal transit alteration and, in general, increased food and water consumption. In conclusion, the observed effects, particularly the anti-inflammatory and antioxidant effects of EOHc, as well as its previously reported low toxicity, position EOHc as a promising candidate for reducing gastrointestinal side effects associated with the use of MTX.</div></div>","PeriodicalId":101014,"journal":{"name":"Pharmacological Research - Natural Products","volume":"5 ","pages":"Article 100112"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Natural Products","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950199724001009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Methotrexate (MTX) is an important drug for the treatment of cancer and other diseases. However, it induces many gastrointestinal inflammation-related side effects. The essential oil of Hyptis crenata (EOHc) has gastrointestinal protective and anti-inflammatory properties. Therefore, we aimed to investigate the effect of EOHc on MTX-induced intestinal inflammation in rats. Male Wistar rats were administered MTX or Saline for 3 days and EOHc (300 mg/kg) or vehicle for an additional 3 or 7 days. Half of the animal was euthanized 3 days after the end of MTX treatment (inflammation phase) and the remaining half euthanized 4 days later (post-inflammation phase). The MPO levels in the mucositis inflammation-related phase of the MTX-treated group were 284 % of the control in the duodenum (cont: 50,9 ± 9,97 U/mg of protein) and 231 % of the control in the ileum (cont: 30,4 ± 6,60 U/mg of protein). In the EOHc group, the levels were 50 % of control in the duodenum and 113 % in the ileum. During this phase, EOHc prevented the increase in TBARs levels and the decrease in thiol levels in the duodenum and jejunum. In the post-inflammation phase of mucositis, EOHc prevented the gastrointestinal transit alteration and, in general, increased food and water consumption. In conclusion, the observed effects, particularly the anti-inflammatory and antioxidant effects of EOHc, as well as its previously reported low toxicity, position EOHc as a promising candidate for reducing gastrointestinal side effects associated with the use of MTX.